The therapeutic role of the combination of HMA with immune checkpoint inhibitors (PD-1, PD-L1, and/or CTLA-4 inhibitors) in AML and MDS, which has been discussed in a recent review [101], is currently being evaluated in a number of ongoing phase 1/2 clinical trials. Here, CD274 is linked to myelodysplastic syndrome.